Allena Pharmaceuticals, Inc.
ALNAQ · OTC
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.29 | 0.02 | -0.05 | 0.05 |
| FCF Yield | -240.63% | -69.24% | -72.26% | -28.45% |
| EV / EBITDA | 0.32 | -0.51 | -0.87 | -1.73 |
| Quality | ||||
| ROIC | -169.31% | -96.63% | -167.95% | -59.76% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.39 | 0.86 | 0.92 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -60.87% | 34.16% | -36.06% | -52.24% |
| Safety | ||||
| Net Debt / EBITDA | 0.92 | 0.76 | 0.41 | 1.45 |
| Interest Coverage | -63.40 | 62.72 | -173.78 | -61.90 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |